Dermata Therapeutics, Inc (DRMA) Misses Q2 EPS by 19c

Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q2 EPS of ($0.74), $0.19 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.

You May Also Be Interested In

• Paramount Weighs Tapping Musk For Equity Investment - Semafor
• McDonald's (MCD) Said August In Us Business Was 'slightly Negative' - Bloomberg
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)